Larger cohorts are expected to shed light on the potential use of adropin as an additional biomarker to diagnose better and predict the prognosis of chronic liver disease and as a potential new therapeutic target in cirrhosis and hepatorenal syndrome. The gene discussed is ENHO; the disease is hepatorenal syndrome.